Is Sutro Biopharma, Inc. (STRO) a Buy, Sell, or Hold?
NASDAQ : STRO
Sutro Biopharma, Inc. — Institutional Ownership
$22.05 USD
-$2.99 (-11.94%)
- Volume
- 924.49K
- Average Volume
- 315.1K
- Market Capitalization
- $213.38M
- P/E Ratio
- -1.27
- Dividend Yield
- 0.00%
- Price Target
- $50.00
- Year High
- $43.85
- Year Low
- $7.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $26.35
Institutional Ownership Summary
Institutional Ownership %
%
Investors Holding
change: 0.0 | last:
Increased Positions
change: 0.0 | last:
Reduced Positions
change: 0.0 | last:
New Positions
change: 0.0 | last:
Sold Positions
change: 0.0 | last:
Total Calls
-
Total Puts
-
Put-Call Ratio
change: 0.0 | last:
Total Invested
-
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-07-30 | BlackRock, Inc. | 1.07M | 6.40% |
| 2026-05-15 | Samsara BioCapital, L.P. | 419.1K | 2.50% |
| 2026-05-15 | Kynam Capital Management, LP | - | 5.27% |
| 2026-05-14 | Affinity Asset Advisors, LLC | 1.07M | 6.50% |
| 2026-05-01 | Point72 Asset Management, L.P. | 946.83K | 5.70% |
| 2026-04-21 | Millennium Management LLC | 210.38K | 1.30% |
| 2026-04-21 | Perceptive Advisors LLC | 898.02K | 5.40% |
| 2026-02-18 | BIOTECHNOLOGY VALUE FUND L P | 668.69K | 4.10% |
| 2026-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | - | 0.00% |
| 2026-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | - | 0.00% |
| 2026-01-29 | Affinity Asset Advisors, LLC | 748.38K | 8.80% |
| 2025-10-23 | Affinity Healthcare Fund, LP | 6.58M | 7.77% |
| 2025-08-14 | RA Capital Management, L.P. | - | 0.00% |
| 2025-08-13 | Suvretta Capital Management, LLC | 6.49M | 7.70% |
| 2025-07-29 | The Vanguard Group | 4.12M | 4.87% |
| 2025-07-16 | BlackRock, Inc. | 2.09M | 2.50% |
| 2025-06-30 | Millennium Management LLC | 4.72M | 5.60% |
| 2025-05-15 | Kynam Capital Management, LP | - | 6.44% |
| 2025-04-17 | BlackRock, Inc. | 6.14M | 7.30% |
| 2025-04-04 | RA Capital Management, L.P. | 4.43M | 5.30% |
| 2024-04-05 | Steven A. Cohen | 5.93M | 7.90% |
| 2024-04-05 | Point72 Asset Management, L.P. | 5.79M | 7.70% |
| 2024-04-05 | Cubist Systematic Strategies, LLC | 141.4K | 0.20% |
| 2024-04-05 | Point72 Capital Advisors, Inc. | 5.79M | 7.70% |
| 2024-01-17 | Millennium Group Management LLC | 3.45M | 5.70% |
| 2024-01-17 | Israel A. Englander | 3.45M | 5.70% |
| 2024-01-17 | Millennium Management LLC | 3.45M | 5.70% |
| 2024-01-17 | Integrated Core Strategies (US) LLC | 3.11M | 5.10% |
| 2023-10-10 | Adage Capital Partners GP, L.L.C. | 3.55M | 5.86% |
| 2023-10-10 | Adage Capital Management, L.P. | 3.55M | 5.86% |
| 2023-10-10 | Phillip Gross | 3.55M | 5.86% |
| 2023-10-10 | Robert Atchinson | 3.55M | 5.86% |
| 2023-10-10 | Adage Capital Partners, L.P. | 3.55M | 5.86% |
| 2023-02-10 | David Rosen | 3.21M | 5.59% |
| 2023-02-10 | LP | 3.21M | 5.59% |
| 2022-07-08 | Millennium Group Management LLC | 2.42M | 5.20% |
| 2022-07-08 | Millennium Management LLC | 2.42M | 5.20% |
| 2022-07-08 | Israel A. Englander | 2.42M | 5.20% |
| 2022-02-14 | Eventide Asset Management, LLC | 2.71M | 5.90% |
| 2022-02-11 | Aaron Cowen | 2.47M | 5.40% |
| 2022-02-11 | Averill Master Fund, Ltd. | 2.47M | 5.40% |
| 2022-02-11 | Suvretta Capital Management, LLC | 2.47M | 5.40% |
| 2022-02-03 | (1) BlackRock, Inc. | 3.7M | 8.00% |
| 2022-01-18 | Mark N. Lampert | 3.16M | 6.80% |
| 2022-01-18 | BVF Inc. | 3.16M | 6.80% |
| 2022-01-18 | Biotechnology Value Fund II, L.P. | 1.24M | 2.70% |
| 2022-01-18 | BVF I GP LLC | 1.71M | 3.70% |
| 2022-01-18 | BVF GP HOLDINGS LLC | 2.95M | 6.40% |
| 2022-01-18 | Biotechnology Value Trading Fund OS LP | 156.74K | 1.00% |
| 2022-01-18 | BVF Partners OS Ltd. | 156.74K | 1.00% |
| 2022-01-18 | Biotechnology Value Fund, L.P. | 1.71M | 3.70% |
| 2022-01-18 | BVF II GP LLC | 1.24M | 2.70% |
| 2022-01-18 | BVF Partners L.P. | 3.16M | 6.80% |
| 2021-12-10 | Averill Master Fund, Ltd. | 2.41M | 5.20% |
| 2021-12-10 | Aaron Cowen | 2.41M | 5.20% |
| 2021-12-10 | Suvretta Capital Management, LLC | 2.41M | 5.20% |
| 2021-04-05 | BRISTOL-MYERS SQUIBB COMPANY 22-0790350 | 1.73M | 3.80% |
| 2021-04-05 | CELGENE CORPORATION 22-2711928 | 1.73M | 3.80% |
| 2021-02-16 | Ridgeback Capital Management LLC 42-1684320 | 1.14M | 2.50% |
| 2021-02-16 | 66-0677421 | 1.14M | 2.50% |
| 2021-02-16 | 72-1614961 | 1.14M | 2.50% |
| 2021-02-12 | Eventide Asset Management, LLC | 2.37M | 5.30% |
| 2021-02-12 | Biotechnology Value Fund, L.P. | 979.45K | 2.20% |
| 2021-02-12 | BVF Partners L.P. | 1.85M | 4.10% |
| 2021-02-12 | BVF Inc. | 1.85M | 4.10% |
| 2021-02-12 | BVF Partners OS Ltd. | 119.18K | 1.00% |
| 2021-02-12 | BVF II GP LLC | 719.66K | 1.60% |
| 2021-02-12 | Biotechnology Value Trading Fund OS LP | 119.18K | 1.00% |
| 2021-02-12 | BVF GP HOLDINGS LLC | 1.7M | 3.80% |
| 2021-02-12 | Mark N. Lampert | 1.85M | 4.10% |
| 2021-02-12 | BVF I GP LLC | 979.45K | 2.20% |
| 2021-02-12 | Biotechnology Value Fund II, L.P. | 719.66K | 1.60% |
| 2021-02-02 | (1) BlackRock, Inc. | 2.72M | 6.20% |
| 2020-08-28 | Oleg Nodelman | 2.33M | 11.00% |
| 2020-08-28 | EcoR1 Capital, LLC | 2.33M | 11.00% |
| 2020-08-28 | EcoR1 Capital Fund Qualified, L.P. | 1.97M | 11.00% |
| 2020-08-25 | Ridgeback Capital Investments L.P. 00-0000000 | 2.01M | 5.30% |
| 2020-08-25 | Ridgeback Capital Management LLC 42-1684320 | 2.01M | 5.30% |
| 2020-08-25 | Ridgeback Capital Investments Ltd. 00-0000000 | 2.01M | 5.30% |
| 2020-05-22 | Biotechnology Value Fund, L.P. | 1.24M | 3.50% |
| 2020-05-22 | BVF II GP LLC | 934.34K | 2.60% |
| 2020-05-22 | BVF Partners L.P. | 2.37M | 6.60% |
| 2020-05-22 | BVF Partners OS Ltd. | 160.47K | 1.00% |
| 2020-05-22 | BVF GP HOLDINGS LLC | 2.16M | 6.00% |
| 2020-05-22 | BVF Inc. | 2.37M | 6.60% |
| 2020-05-22 | Mark N. Lampert | 2.37M | 6.60% |
| 2020-05-22 | Biotechnology Value Trading Fund OS LP | 160.47K | 1.00% |
| 2020-05-22 | Biotechnology Value Fund II, L.P. | 924.34K | 2.60% |
| 2020-05-22 | BVF I GP LLC | 1.24M | 3.50% |
| 2020-02-12 | Skyline Venture Management V, LLC | 1.96M | 8.50% |
| 2020-02-12 | John G. Freund | 1.96M | 8.50% |
| 2020-02-12 | Yasunori Kaneko | 1.96M | 8.50% |
| 2020-02-12 | Skyline Venture Partners V, L.P. | 1.96M | 8.50% |
| 2020-02-10 | CELGENE | 1.73M | 7.50% |
| 2019-02-14 | Lilly Ventures Fund I, LLC | 1.54M | 6.70% |
| 2019-02-14 | S. Edward Torres | 1.54M | 6.70% |
| 2019-02-14 | LV Management Group, LLC | 1.54M | 6.70% |
| 2019-02-14 | Steven E. Hall, Ph.D. | 1.54M | 6.70% |
| 2019-02-14 | Armen B. Shanafelt, Ph.D. | 1.54M | 6.70% |
| 2019-02-13 | Eventide Asset Management, LLC | 1.24M | 5.40% |
| 2019-02-12 | Daniel Janney | 1.95M | 8.50% |
| 2019-02-12 | Alta Partners VIII, L.P. | 1.94M | 8.50% |
| 2019-02-12 | Guy Nohra | 1.94M | 8.50% |
| 2019-02-12 | Alta Partners Management VIII, LLC | 1.94M | 8.50% |
| 2019-02-12 | Farah Champsi | 1.94M | 8.50% |
| 2018-10-09 | International Life Sciences Fund III (LP1), L.P. | 942.79K | 4.10% |
| 2018-10-09 | SV Life Sciences Fund V Strategic Partners, L.P. | 881.75K | 3.90% |
| 2018-10-09 | L.P. | 942.79K | 4.10% |
| 2018-10-09 | Co-Investment, | 942.79K | 4.10% |
| 2018-10-09 | International Life Sciences Fund III (GP), L.P. | 942.79K | 4.10% |
| 2018-10-09 | ILSF III, LLC | 942.79K | 4.10% |
| 2018-10-09 | SV Life Sciences Fund V (GP), L.P. | 881.75K | 3.90% |
| 2018-10-09 | SV Life Sciences Fund V, L.P. | 881.75K | 3.90% |
| 2018-10-09 | SVLSF V, LLC | 881.75K | 3.90% |
| 2018-10-04 | Merck & Co., Inc. | 2.72M | 11.90% |
| 2018-10-04 | 2. | 10.0 | 7.70% |
| 2018-10-04 | 2. | 10.0 | 7.70% |
| 2018-10-04 | 2. | 10.0 | 7.70% |
| 2018-10-04 | 2. | 10.0 | 7.70% |
| 2018-10-04 | Merck Sharp & Dohme Corp. | 2.72M | 11.90% |
STRO Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $11.57 | 8.5M | $98.32M | $58.13M | $15.67M | $55.86M |
| 2024-12-31 | $18.40 | 7.68M | $141.37M | $190.3M | $23.15M | -$25.78M |
| 2023-12-31 | $42.90 | 6.02M | $258.1M | $69.27M | $33.64M | $222.47M |
| 2022-12-31 | $80.80 | 5.07M | $409.97M | $47.25M | $55.02M | $417.73M |
| 2021-12-31 | $148.80 | 4.61M | $686.25M | $30.41M | $57.37M | $713.21M |
| 2020-12-31 | $217.10 | 3.26M | $707.17M | $206.15M | $24.54M | $525.56M |
| 2019-12-31 | $110.00 | 2.3M | $252.54M | $4.96M | $9.88M | $257.46M |
| 2018-12-31 | $90.20 | 2.29M | $206.17M | $125.3M | $14.72M | $95.59M |
| 2017-12-31 | $152.00 | 699.74K | $106.36M | $22.02M | $14.63M | $98.97M |
| 2016-12-31 | $152.00 | 44120 | $6.71M | $11.59M | $1.19M | -$3.69M |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | $33.20 | 16.57M | $550.18M | $54.34M | $10.78M | $506.63M |
| 2026-03-31 | $24.91 | 13.08M | $325.88M | $73.68M | $13.63M | $265.83M |
| 2025-12-31 | $11.57 | 8.58M | $99.32M | $58.13M | $235.21M | $276.4M |
| 2025-09-30 | $8.68 | 8.49M | $73.67M | $65.93M | $17.66M | $25.4M |
| 2025-06-30 | $7.14 | 8.46M | $60.39M | $64.02M | $219.68M | $216.04M |
| 2025-03-31 | $6.51 | 8.31M | $54.1M | $106.23M | $21.4M | -$30.73M |
| 2024-12-31 | $18.40 | 8.25M | $151.85M | $190.3M | $23.15M | -$15.3M |
| 2024-09-30 | $34.60 | 8.2M | $283.87M | $174.58M | $24.86M | $134.16M |
| 2024-06-30 | $30.50 | 8.12M | $247.74M | $90.79M | $26.53M | $183.47M |
| 2024-03-31 | $53.30 | 6.15M | $327.57M | $65.22M | $28.07M | $290.42M |
| 2023-12-31 | $42.90 | 6.1M | $261.73M | $69.27M | $33.64M | $226.1M |
| 2023-09-30 | $34.70 | 6.06M | $210.28M | $81.83M | $38.18M | $166.62M |